Methods of increasing the expression yield of vitamin K-dependent proteins
US-9212214-B2 · Dec 15, 2015 · US
Cell growth promoter and application thereof
US12559715B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12559715-B2 |
| Application number | US-202418668297-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2024 |
| Priority date | Jul 12, 2023 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A cell growth promoter and an application thereof are provided. The invention adopts Fe 2+ and ovalbumin to form a Fe 2+ -ovalbumin (OVA) compound to promote ovalbumin cell endocytosis, the cell growth promoter can maintain cell growth in an environment free of amino acids, promote cell proliferation in an environment with amino acids; and, the Fe 2+ -OVA compound can replace expensive animal serum albumin in cell culture, the cell growth promoter has a significant effect on improving cell viability and is low cost.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method for improving a cell viability, comprising the steps of preparing a Fe 2+ -ovalbumin (OVA) compound by adding a solution of OVA to a solution of Fe 2+ and incubating at 37° C. for 15 minutes, wherein a molar ratio of the OVA to the Fe 2+ is 1:0.5-4; diluting the Fe 2+ -OVA compound in cell culture medium, wherein a final concentration of Fe 2+ added is 10-100 μM, and a final concentration of OVA added is 10-100 μM; and adding the cell culture medium containing the Fe 2+ -OVA compound to a mammalian cell, wherein the method is for non-diagnostic or non-therapeutic purposes. 2 . The method for improving the cell viability according to claim 1 , wherein the method is performed in an environment being free of an amino acid or animal serum albumin. 3 . The method for improving the cell viability according to claim 1 , wherein in the method, an animal serum albumin is replaced with the Fe 2+ -OVA compound.
Assignees
Inventors
Classifications
Proteins not provided for elsewhere · CPC title
Serum-free medium, which may still contain naturally-sourced components · CPC title
Iron; Fe chelators; Transferrin · CPC title
Amino acids, peptides or proteins · CPC title
Calcium; Ca chelators; Calcitonin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12559715B2 cover?
- A cell growth promoter and an application thereof are provided. The invention adopts Fe 2+ and ovalbumin to form a Fe 2+ -ovalbumin (OVA) compound to promote ovalbumin cell endocytosis, the cell growth promoter can maintain cell growth in an environment free of amino acids, promote cell proliferation in an environment with amino acids; and, the Fe 2+ -OVA compound can replace expensive animal …
- Who is the assignee on this patent?
- Univ China Agricultural
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0037. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).